BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...new evidence and price,” said ICER CMO David Rind. Going long What set Revlimid and Genvoya...
...apart was new evidence of added benefit over existing treatments based on long-term data. For Genvoya...
...Sciences Inc. (NASDAQ:GILD) submitted long-term data from randomized controlled trials to ICER that showed that Genvoya...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Enbrel etanercept $5,782.8 $3,925.2 $5,233.6 -9% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya...
BioCentury | May 1, 2018
Company News

HCV drug sales drag down Gilead's 1Q18 earnings

...its 4Q16 sales figures of $3.2 billion (see BioCentury Extra, Feb. 6) . HIV drugs Genvoya...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...5% Gilead Sciences Inc. (NASDAQ:GILD) Epclusa sofosbuvir/velpatasvir $1,752.0 $2,945.0 $3,926.7 124% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya...
BioCentury | May 3, 2017
Company News

Gilead HCV sales continue to weaken

...partially offset by growth in HIV. The company reported $769 million in 1Q17 sales of Genvoya...
...TAF), up from $158 million in 1Q16 and beating the $647.9 million consensus. FDA approved Genvoya...
...consensus. The company gained $0.48 to $68.59 on Tuesday, and reported earnings after market close. Becky Simon Genvoya Harvoni Sovaldi Gilead...
BioCentury | Feb 8, 2017
Company News

Gilead HCV outlook souring

...category rose to $3.4 billion in 4Q16, up from $3 billion in 4Q15. Sales of Genvoya...
BioCentury | Nov 1, 2016
Financial News

Gilead maintains guidance as HCV sales shrink

...3Q15. The company attributed the increase largely to uptake of tenofovir alafenamide-based treatments such as Genvoya...
BioCentury | Jul 25, 2016
Top Story

Gilead lowers guidance amid slowing HCV sales

...of HIV treatment Genvoya were $302 million in 2Q16, beating the consensus estimate. FDA approved Genvoya...
BioCentury | Apr 18, 2016
Company News

Gilead sales and marketing update

...and Efficiency in Health Care (IQWiG) issued a dossier of early benefit assessment for Genvoya tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine...
BioCentury | Feb 15, 2016
Company News

Gilead, Japan Tobacco, AIDS Healthcare Foundation, Emory University infectious news

...of Gilead’s patents covering TAF.” The non-profit said Gilead’s November 2015 launch of HIV drug Genvoya...
...argued Gilead “knowingly, willfully, and wrongfully maintained its monopoly power by improperly bundling” TAF into Genvoya...
...wishing to enter the market would have to invalidate all 12 Orange Book patents covering Genvoya...
Items per page:
1 - 10 of 26